Alliance Pharma (APH)

Sector:

Pharma and Biotech

Index:

FTSE AIM 50

46.10p
   
  • Change Today:
      0.25p
  • 52 Week High: 49.55
  • 52 Week Low: 29.35
  • Currency: UK Pounds
  • Shares Issued: 540.57m
  • Volume: 324,847
  • Market Cap: £249.20m
  • RiskGrade: 119
  • Beta: 0.92

Growth Ratings

EPS Growth shows the relative growth of a company's earnings over the last year.

The rise in total monies receivable for goods / services sold before expenses.

1yr EPS Growth
12.03% above the market average12.03% above the market average12.03% above the market average12.03% above the market average12.03% above the market average
20.00% above the sector average20.00% above the sector average20.00% above the sector average20.00% above the sector average20.00% above the sector average
1yr Revenue Growth
14.49% above the market average14.49% above the market average14.49% above the market average14.49% above the market average14.49% above the market average
12.50% above the sector average12.50% above the sector average12.50% above the sector average12.50% above the sector average12.50% above the sector average

Income Ratings

The percentage of the share price that a company pays out as dividends over a year.

The percentage change from the previous year in the dividend paid on each share.

Dividend Yield Not Available
1yr DPS Growth Not Available

Valuation Ratings

The share price as a ratio of revenue per share.

The share price as a ratio of net asset value.

Price Sales Ratio
21.8% below the market average21.8% below the market average21.8% below the market average21.8% below the market average21.8% below the market average
85.71% below the sector average85.71% below the sector average85.71% below the sector average85.71% below the sector average85.71% below the sector average
Price Book Ratio
10.16% below the market average10.16% below the market average10.16% below the market average10.16% below the market average10.16% below the market average
44.19% above the sector average44.19% above the sector average44.19% above the sector average44.19% above the sector average44.19% above the sector average

Performance Ratings

In percentage total change in share price over 30 days.

In percentage total change in share price over 3 months.

Price Chg 30d
55.26% above the market average55.26% above the market average55.26% above the market average55.26% above the market average55.26% above the market average
48.00% above the sector average48.00% above the sector average48.00% above the sector average48.00% above the sector average48.00% above the sector average
Price Chg 3m
62.19% above the market average62.19% above the market average62.19% above the market average62.19% above the market average62.19% above the market average
52.00% above the sector average52.00% above the sector average52.00% above the sector average52.00% above the sector average52.00% above the sector average

Technical Ratings

The Relative Strength Index measures a share price relative to itself and its recent history.

Momentum is an oscillator that measures the rate of price change.

RSI
45.70% above the market average45.70% above the market average45.70% above the market average45.70% above the market average45.70% above the market average
39.13% above the sector average39.13% above the sector average39.13% above the sector average39.13% above the sector average39.13% above the sector average
Momentum 20
40.94% above the market average40.94% above the market average40.94% above the market average40.94% above the market average40.94% above the market average
47.83% above the sector average47.83% above the sector average47.83% above the sector average47.83% above the sector average47.83% above the sector average

Management Ratings

Operating Margin is profit as a percentage of sales.

Return on capital employed measures the return from invested and borrowed capital.

Operating Margin
57.19% below the market average57.19% below the market average57.19% below the market average57.19% below the market average57.19% below the market average
33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average
ROCE Not Available

Profitability Ratings

Earnings per share, the company's profitability expressed on a per share basis.

Analysts' estimates of future EPS for the next 2 years.

EPS
11.92% above the market average11.92% above the market average11.92% above the market average11.92% above the market average11.92% above the market average
67.35% above the sector average67.35% above the sector average67.35% above the sector average67.35% above the sector average67.35% above the sector average
Forecast EPS
68.25% below the market average68.25% below the market average68.25% below the market average68.25% below the market average68.25% below the market average
77.78% below the sector average77.78% below the sector average77.78% below the sector average77.78% below the sector average77.78% below the sector average

Profit/Loss Ratings

Monies produced from sales of goods and services after trade discounts, VAT, etc.

Operating Profit is the profit after deducting operating costs from gross profits.

Turnover
39.43% above the market average39.43% above the market average39.43% above the market average39.43% above the market average39.43% above the market average
66.67% above the sector average66.67% above the sector average66.67% above the sector average66.67% above the sector average66.67% above the sector average
Operating Profit Loss
94.66% below the market average94.66% below the market average94.66% below the market average94.66% below the market average94.66% below the market average
87.76% below the sector average87.76% below the sector average87.76% below the sector average87.76% below the sector average87.76% below the sector average

Balance Sheet Ratings

The difference between current assets and current liabilities.

A current asset representing the company's financial liquidity.

Assets
41.75% above the market average41.75% above the market average41.75% above the market average41.75% above the market average41.75% above the market average
57.45% above the sector average57.45% above the sector average57.45% above the sector average57.45% above the sector average57.45% above the sector average
Cash
35.51% above the market average35.51% above the market average35.51% above the market average35.51% above the market average35.51% above the market average
58.33% above the sector average58.33% above the sector average58.33% above the sector average58.33% above the sector average58.33% above the sector average

Director Deal Ratings

The cumulative amount of stocks sold by company directors over 1 year

The cumulative amount of stocks bought by company directors over 1 year

Sells 1y Not Available
Buys 1y Not Available

Broker Ratings

The percentage of stockbrokers that rate the company as a Buy

The percentage of stockbrokers that rate the company as a Hold

Brokers Percent Buy
53.68% below the market average53.68% below the market average53.68% below the market average53.68% below the market average53.68% below the market average
73.33% below the sector average73.33% below the sector average73.33% below the sector average73.33% below the sector average73.33% below the sector average
Brokers Percent Neutral
42.77% above the market average42.77% above the market average42.77% above the market average42.77% above the market average42.77% above the market average
Sector averageSector averageSector averageSector averageSector average

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Alliance Pharma Market Data

Currency UK Pounds
Share Price 46.10p
Change Today 0.25p
% Change 0.55 %
52 Week High 49.55
52 Week Low 29.35
Volume 324,847
Shares Issued 540.57m
Market Cap £249.20m
Beta 0.92
RiskGrade 119

Alliance Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
14.62% below the market average14.62% below the market average14.62% below the market average14.62% below the market average14.62% below the market average
64.00% above the sector average64.00% above the sector average64.00% above the sector average64.00% above the sector average64.00% above the sector average
Price Trend
50.88% above the market average50.88% above the market average50.88% above the market average50.88% above the market average50.88% above the market average
79.59% above the sector average79.59% above the sector average79.59% above the sector average79.59% above the sector average79.59% above the sector average
Income Not Available
Growth
38.06% below the market average38.06% below the market average38.06% below the market average38.06% below the market average38.06% below the market average
33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average

What The Brokers Say

Strong Buy 4
Buy 0
Neutral 3
Sell 0
Strong Sell 0
Total 7
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Alliance Pharma Dividends

  Latest Previous
  Final Interim
Ex-Div 22-Jun-23 22-Dec-22
Paid 18-Jul-23 19-Jan-23
Amount 1.18p 0.59p

Trades for 20-Dec-2024

Time Volume / Share Price
16:29 76 @ 46.45p
16:28 207 @ 46.10p
16:22 4 @ 46.00p
16:15 64 @ 46.40p
16:13 140 @ 46.15p

Alliance Pharma Key Personnel

CFO Andrew Franklin
Chair Camillo Pane
CEO Nick Sedgwick

Top of Page